Replies to post #387590 on Elite Pharmaceuticals Inc (ELTP)

[Pharma Sleuth]

Because it's been heavily manipulated for a long time. By your team here.

Company is highly profitable. Has earnings and a real PE despite spending millions on R&D at the same time.

Now those millions are coming to bear fruit

Multiple drugs pending approval, filing announcements, trials. $10 billion dollars worth.

OXY filing possible first to file possibly days away.
$5.1B filing due any time now

Plus other "needle movers" bigger then Adderall

Just off the top of my head

Includes still manufacturing Adderall...as much as they can get their hands on.

Prasco Adderall XR launching in January which could easily be 100-200m a year very possibly if not more.

So you have to come here and post nonsense every day. It's the only explanation

[mrwrn2010]

Because institutional funds largely can’t own ELTP shares while it is a penny stock.

Because a chunk of brokerages won’t let you trade ELTP at all.

Because the company pivoted from its original abuse deterrent goal and probably scared off some would-be investors from a few rounds of overpromising and under delivering.

Because Elite had to dilute its shares to stay in business and continue funding new drugs, which drags on price.

Because stocks of all calibers go through periods of simply being undervalued or overvalued irrespective of fundamentals.

Because certain individuals admit to having engaged in shorting campaigns on Elite, which drags on price.

Because we’re on the OTC and during periods of extremely low volume, market makers will play games, which drags on price.

We have multiple drugs in the pipeline, plus already approved, that equal several billion dollars in market size. Nasrat is not going to sell the company for not even a double in share price from here when they’ve had independent valuations for over $1 years ago. Seriously, give it a rest.

Doesn’t matter what your personal price target is - it isn’t going to happen.

[NASDAQ2020]

Sorry you had to work this Sunday.